STOCK TITAN

Nexgel Inc Stock Price, News & Analysis

NXGL Nasdaq

Welcome to our dedicated page for Nexgel news (Ticker: NXGL), a resource for investors and traders seeking the latest updates and insights on Nexgel stock.

Nexgel Inc (NXGL) specializes in advanced hydrogel solutions for medical, cosmetic, and diagnostic applications through proprietary electron beam cross-linking technology. This page provides centralized access to official corporate announcements and strategic developments.

Investors and industry professionals will find verified updates including earnings reports, product launch details, regulatory milestones, and partnership announcements. Our curated news collection enables efficient tracking of NXGL's innovations in transdermal drug delivery systems and FDA-approved wound care solutions.

Key content categories include:
- Financial performance updates and SEC filings
- New hydrogel product releases across medical and consumer markets
- Manufacturing process innovations and patent developments
- Strategic collaborations in healthcare and cosmetics sectors

Bookmark this page for real-time access to NXGL's corporate communications and market-moving announcements. For comprehensive analysis of hydrogel industry trends, visit Stock Titan's research portal regularly.

Rhea-AI Summary

NEXGEL has announced promising results from a study published in SAGE Journals regarding its SilverSeal hydrogel dressing. The study involved 40 foot and ankle patients and evaluated post-surgical scarring and complications. Results showed that patients using SilverSeal experienced significant improvements in scar quality, reduced pain, and lower itching at the surgical site compared to those with a standard petroleum-based dressing. No postoperative complications were reported in either group, suggesting SilverSeal's potential in enhancing surgical recovery.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.66%
Tags
none
-
Rhea-AI Summary

NEXGEL, Inc. (NASDAQ: NXGL, NXGLW) has appointed Dr. Neil Chesen and Dr. Leonard Nelson to its Scientific Advisory Board. Dr. Nelson is a pediatric ophthalmology leader with extensive credentials, including roles at Wills Eye Hospital and Thomas Jefferson University. Dr. Chesen is a seasoned ophthalmologist with over 33 years of experience. Their addition aims to enhance NEXGEL's development of high-water-content hydrogel products for healthcare applications. CEO Adam Levy emphasized that their expertise will significantly aid in advancing the company's innovative hydrogel solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.58%
Tags
management
-
Rhea-AI Summary

NEXGEL, Inc. (NASDAQ: NXGL, NXGLW) announced that CEO Adam Levy will present at the H.C. Wainwright 24th Annual Global Investment Conference taking place from September 12-14, 2022. The presentation is scheduled for September 14, from 9:00 A.M. to 9:30 A.M. Eastern Time. Interested investors can contact their H.C. Wainwright representative or email NEXGEL@kcsa.com for 1x1 meetings. NEXGEL specializes in high-water-content hydrogel products for healthcare and consumer applications, having over two decades of experience in developing these innovative solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.11%
Tags
conferences
Rhea-AI Summary

NEXGEL reported a 35% year-over-year revenue growth to $561 thousand for Q2 2022, showing a 42% sequential increase. The rise is attributed to successful launches and demand for branded products, such as MEDAGEL Pro Pads. Gross profit improved to $101 thousand, with an 18% margin. However, operating expenses rose to $819 thousand, driven by increased R&D investments and higher SG&A costs. As of June 30, 2022, cash and equivalents stood at $9.7 million, ensuring a solid financial position for ongoing growth initiatives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.12%
Tags
-
Rhea-AI Summary

NEXGEL (NASDAQ: NXGL) will report its financial and operating results for Q2 2022 on August 10, 2022, after market close. Following the release, a conference call will be held at 4:30 P.M. ET the same day. Interested individuals can join the call via a U.S. toll-free number or international dial-in options, and a webcast will be available on the company’s Investor Relations website. A replay of the call will be accessible until August 17, 2022. NEXGEL specializes in high-water-content hydrogel products for healthcare and consumer applications.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.74%
Tags
conferences
-
Rhea-AI Summary

NEXGEL (NASDAQ: NXGL, NXGLW) has launched the MEDAGEL Hydroliner Pro pads designed to protect eyelashes during cosmetic services like extensions and lifts. These pads offer a breathable, flexible, and skin-friendly alternative to traditional options, preventing slippage while being gentle on sensitive skin. They aim to enhance client comfort, allowing for easy removal and replacement during the application process. This product marks NEXGEL's first proprietary business-to-business offering, expanding its innovative hydrogel product line.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.65%
Tags
none
Rhea-AI Summary

NEXGEL (NASDAQ: NXGL, NXGLW) has launched a partnership with Partners for World Health to provide humanitarian support in Ukraine. For every two boxes of SilverSeal® purchased, one will be donated to those in need. In June, 458 boxes were donated, equating to 1,832 healing patches. CEO Adam Levy emphasized the importance of treating skin injuries in crisis zones. The initiative addresses urgent medical needs amid ongoing conflict, aiming to deliver essential supplies through various shipping methods.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.09%
Tags
none
-
Rhea-AI Summary

NEXGEL, Inc. (NASDAQ: NXGL) reported a 48% year-over-year revenue increase to $396 thousand for Q1 2022, driven by new product launches in its consumer segment. The company introduced two new OTC products: the MEDAGEL ClearComfort Hydrogel Patch and the MEDAGEL Bug Bite Relief Patch. Gross loss improved to $22 thousand from $42 thousand last year, although operating expenses rose to $790 thousand. Cash reserves decreased to $10.5 million due to principal payments on notes payable. The company forecasts continued revenue growth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.77%
Tags
-
Rhea-AI Summary

NEXGEL, a provider of high-water-content hydrogel products, will announce its first quarter 2022 financial and operating results on May 12, 2022, after market closure. A conference call is scheduled for 4:30 PM/ET on the same day to discuss these results. The call can be accessed via toll-free numbers and will be webcast live, with an archive available for 90 days. The company specializes in skin-friendly hydrogels, developing over 200 combinations using natural ingredients for long-term wear with minimal irritation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.16%
Tags
conferences
Rhea-AI Summary

NEXGEL, a provider of high-water-content hydrogel products, announces CEO Adam Levy's participation at the Planet MicroCap Showcase 2022 from May 3-5, 2022, in Las Vegas. Levy's presentation is scheduled for May 4, 2022, at 10:30 AM PT, with a webcast accessible for those unable to attend. Interested investors can book 1x1 meetings during the conference. NEXGEL specializes in gentle skin patches utilizing over 200 formulations and has been developing hydrogels for over 20 years.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.43%
Tags
conferences

FAQ

What is the current stock price of Nexgel (NXGL)?

The current stock price of Nexgel (NXGL) is $2.66 as of May 2, 2025.

What is the market cap of Nexgel (NXGL)?

The market cap of Nexgel (NXGL) is approximately 19.4M.
Nexgel Inc

Nasdaq:NXGL

NXGL Rankings

NXGL Stock Data

19.36M
6.35M
20.56%
6.19%
1.52%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States
LANGHORNE